I have followed the work on this new agent in the last few years. I tried to test it in CMR perfusion but the company refused it initially. It was only tested with nuclear MPI. On a critical view: the symptoms are about the same as adenosine (ok, there is a statistical difference but I believe clinically irrelevant) but the ease of use really is something to cheer. It would fit CMR very nicely: one single bolus, no weight ajustement, short duration in minutes.
However, as it is, the price is almost prohibitive and it is not approved in all countries yet (at least not in Brazil so far).
If the prices go down (and there are 2 competitors coming along), maybe it will be useful. Otherwise, good old dipyridamole will continue ruling.
No comments:
Post a Comment